Association between serum sex hormone levels and prostate cancer: effect of prostate cancer on serum testosterone levels

被引:9
作者
Imamoto, Takashi [1 ]
Suzuki, Hiroyoshi [1 ]
Utsumi, Takanobu [1 ]
Endo, Takumi [1 ]
Takano, Makoto [1 ]
Yano, Masashi [1 ]
Kawamura, Koji [1 ]
Kamiya, Naoto [1 ]
Nihei, Naoki [1 ]
Naya, Yukio [1 ]
Ichikawa, Tomohiko [1 ]
机构
[1] Chiba Univ, Grad Sch Med, Dept Urol, Chuo Ku, Chiba 2608670, Japan
关键词
5 alpha-reductase inhibitors; dihydrotestosterone; pathological findings; prognosis; risk; tumor grade; RADICAL RETROPUBIC PROSTATECTOMY; HIGH-GRADE; REPLACEMENT THERAPY; PATHOLOGICAL STAGE; 5-ALPHA-REDUCTASE ACTIVITY; INDEPENDENT PREDICTOR; PROGNOSTIC-FACTORS; HYPOGONADAL MEN; HIGH-RISK; FINASTERIDE;
D O I
10.2217/FON.09.82
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Androgens are essential for prostatic growth and development, but also play a significant role in the pathogenesis of prostate disease. The traditional view that higher testosterone levels represent a risk factor for prostate cancer (PCa) appears to have little evidentiary support. Some studies have described a relationship between lower testosterone levels and more advanced disease, Serum androgen levels, within a broad range, are thus suggested to show no association with PCa risk, whereas low rather than high serum testosterone levels have been found to be associated with advanced or high-grade disease at the time of PCa diagnosis. Dihydrotestosterone, the principal prostatic androgen, is transformed from testosterone by type 1 and type 25 alpha-reductose, and therapeutic benefits may thus be potentially achieved through the inhibition of 5 alpha-reductase,
引用
收藏
页码:1005 / 1013
页数:9
相关论文
共 78 条
[1]   Prevention of prostate cancer by androgens:: Experimental paradox or clinical reality [J].
Algarté-Génin, M ;
Cussenot, O ;
Costa, P .
EUROPEAN UROLOGY, 2004, 46 (03) :285-294
[2]  
ANDREEVA Y, 1995, POLAR GEOGRAPHY GEOL, V19, P22
[3]   Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (reduce) trial [J].
Andriole, G ;
Bostwick, D ;
Brawley, O ;
Gomella, L ;
Tindall, D ;
Breed, S ;
Somerville, M ;
Rittmaster, R .
JOURNAL OF UROLOGY, 2004, 172 (04) :1314-1317
[4]   Testosterone replacement therapy and the risk of prostate cancer: a perspective view [J].
Barqawi, AB ;
Crawford, ED .
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2005, 17 (05) :462-463
[5]  
Bhasin S, 2003, J ANDROL, V24, P299
[6]   The Evolving Role of Oestrogens and Their Receptors in the Development and Progression of Prostate Cancer [J].
Bonkhoff, Helmut ;
Berges, Richard .
EUROPEAN UROLOGY, 2009, 55 (03) :533-542
[7]   Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy [J].
Carver, BS ;
Kattan, MW ;
Scardino, PT ;
Eastham, JA .
BJU INTERNATIONAL, 2005, 95 (04) :509-512
[8]   What causes prostate cancer? A brief summary of the epidemiology [J].
Chan, JM ;
Stampfer, MJ ;
Giovannucci, EL .
SEMINARS IN CANCER BIOLOGY, 1998, 8 (04) :263-273
[9]   The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis [J].
Chen, SS ;
Chen, KK ;
Lin, ATL ;
Chang, YH ;
Wu, HH ;
Chang, LS .
BJU INTERNATIONAL, 2002, 89 (07) :710-713
[10]   INDEPENDENT PROGNOSTIC FACTORS IN PATIENTS WITH METASTATIC (STAGE-D2) PROSTATE-CANCER [J].
CHODAK, GW ;
VOGELZANG, NJ ;
CAPLAN, RJ ;
SOLOWAY, M ;
SMITH, JA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (05) :618-621